Cargando…

Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101)

BACKGROUND: Camrelizumab has shown promising survival benefits in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients when used in combination with chemotherapy. However, its effectiveness and safety outside the clinical trial setting are largely unknown. Therefore, we conducted NOA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Rong, Shi, Meiqi, Ji, Mei, Han, Zhengxiang, Chen, Lingxiang, Liu, Yong, Lu, Kaihua, Liu, Lianke, Chen, Bi, Zhang, Xizhi, Miao, Liyun, Shu, Yongqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183390/ https://www.ncbi.nlm.nih.gov/pubmed/37197631 http://dx.doi.org/10.21037/tlcr-23-121

Ejemplares similares

The new Noah
por: Durrell, Gerald, 1925-1995

Noah Morris
Publicado: (1947)

The North Area and its Noah's Ark
Publicado: (1977)

In Memoriam—Henry Noah Martin, M. D.
por: Van Baun, Wm. W.
Publicado: (1890)

Aaron Douglas (1899–1979). Noah's Ark, 1927
por: Smalls, Marcia, et al.
Publicado: (2003)

The World Coral Conservatory (WCC): A Noah's ark for corals to support survival of reef ecosystems
por: Zoccola, Didier, et al.
Publicado: (2020)

Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)
por: Xu, Chong-Rui, et al.
Publicado: (2023)

Long-term survival of an unresectable upper thoracic esophageal squamous cell carcinoma with severe dysphagia following nasogastric tube feeding and camrelizumab-containing therapy: a case report
por: Wang, Tingting, et al.
Publicado: (2020)

Conservation Priorities when Species Interact: The Noah's Ark Metaphor Revisited
por: Courtois, Pierre, et al.
Publicado: (2014)

Mammalian Collection on Noah's Ark: The Effects of Beauty, Brain and Body Size
por: Frynta, Daniel, et al.
Publicado: (2013)

“Noah’s Ark” Project: Interim Results and Outlook for Classic Collection Development
por: Kalyakin, M. V., et al.
Publicado: (2018)

A phase I study investigation of metabolism, and disposition of [(14)C]-anlotinib after an oral administration in patients with advanced refractory solid tumors
por: Liu, Yiqian, et al.
Publicado: (2020)

Noah’s Ark Conservation Will Not Preserve Threatened Ecological Communities under Climate Change
por: Harris, Rebecca Mary Bernadette, et al.
Publicado: (2015)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

In Memoriam—Henry Noah Martin, M. D.: Preamble and Resolutions by the Bœnninghausen Medical Club, of Philadelphia
Publicado: (1889)

Noah, Carolyn B. y Braun, Linda W. The browsable classroom: an introduction to e-Learning for librarians
por: GARDUÑO V., ROBERTO
Publicado: (2004)

Updates to the Noah Land Surface Model in WRF‐CMAQ to Improve Simulated Meteorology, Air Quality, and Deposition
por: Campbell, Patrick C., et al.
Publicado: (2019)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
por: Li, Xiaomi, et al.
Publicado: (2023)

Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study
por: Zhou, Haiyu, et al.
Publicado: (2021)

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
por: Chen, Jinzhang, et al.
Publicado: (2020)

Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China
por: Liu, Haonan, et al.
Publicado: (2022)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
por: Liu, Jun, et al.
Publicado: (2022)

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023)

Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
por: Duan, Xuhua, et al.
Publicado: (2023)

Successful response to camrelizumab in metastatic bladder cancer: A case report
por: Xie, Chen, et al.
Publicado: (2022)

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study
por: Chen, Xiaofeng, et al.
Publicado: (2014)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Yuan, Guosheng, et al.
Publicado: (2020)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
por: Liu, Yanfei, et al.
Publicado: (2023)

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
por: Pu, Xingxiang, et al.
Publicado: (2022)

Dreams Shared on Social Networks during the COVID-19 Pandemic: A Tower of Babel or Noah’s Ark?—A Group-Analytic Perspective
por: Geller, Shulamit, et al.
Publicado: (2023)

Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
por: Ren, Yanqiao, et al.
Publicado: (2022)

Sequential transcatheter arterial chemoembolization, three-dimensional conformal radiotherapy, and high-intensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients
por: Ni, Shengfa, et al.
Publicado: (2012)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Immune-Related Colitis Induced by Camrelizumab: A Case Report
por: Cheng, Sheng, et al.
Publicado: (2023)

Merkel cell carcinoma of the thigh: case report and review of the literature
por: Jiang, Wen, et al.
Publicado: (2019)

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial
por: Mei, Kuimin, et al.
Publicado: (2021)

Abnormal regulation of TSG101 in mice with spongiform neurodegeneration
por: Jiao, Jian, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_atrmgk337amk9roqist1kka8ba